Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Syndromic Surveillance for E-Cigarette, or Vaping, Product Use-Associated Lung Injury.

ABSTRACT:

SUBMITTER: Hartnett KP

PROVIDER: S-EPMC10613510 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature

ACCESS DATA

Json Xml

Publications

Syndromic Surveillance for E-Cigarette, or Vaping, Product Use-Associated Lung Injury.

Hartnett Kathleen P KP Kite-Powell Aaron A Patel Megan T MT Haag Brittani L BL Sheppard Michael J MJ Dias Taylor P TP King Brian A BA Melstrom Paul C PC Ritchey Matthew D MD Stein Zachary Z Idaikkadar Nimi N Vivolo-Kantor Alana M AM Rose Dale A DA Briss Peter A PA Layden Jennifer E JE Rodgers Loren L Adjemian Jennifer J

The New England journal of medicine 20191220 8

PMID: 31860794

Similar Datasets

E-cigarette, or Vaping, Product Use-Associated Lung Injury: Looking Back, Moving Forward.

Project description:Implications In this commentary, we describe the evidence-based approach used to identify the primary cause of EVALI and to curb the 2019 outbreak. We also discuss future research opportunities and public health practice considerations to prevent a resurgence of EVALI.

| S-EPMC7792918 | biostudies-literature

E-cigarette or vaping product use associated lung injury, (EVALI) - A diagnosis of exclusion.

Project description:Inhalation of aerosolized products generated by different electronic devices is called vaping. E-cigarettes or Vaping product use Associated Lung Injury (EVALI) outbreak peaked in August-September 2019 and gradually declined. EVALI remains a diagnosis of exclusion which presents as an acute lung injury in the vaping population. Vitamin E acetate and its products are implicated as one of the cytotoxic agents causing airway centered pneumonitis. Lipid laden macrophages are found in samples of BAL fluid but their role in cytopathology of the disease remains unclear. We present a 57 years old man who came to the emergency department at Monmouth Medical Center, New Jersey in fall, 2019. Reportedly he has been vaping THC about 100g every day for past three days. At initial presentation, he had fever, shortness of breath and hypoxia requiring supplemental oxygen. He was empirically treated with levofloxacin 500 mg for five days without a significant improvement in his symptoms. Non-contrast chest CT scan showed bilateral ground-glass opacities, indicative of diffuse alveolar damage. He underwent flexible bronchoscopy to rule out infective pneumonia followed by auto-immune work-up that was non-conclusive. He was given 1 mg/kg methylprednisolone with a quick taper of oral steroids leading to the resolution of symptoms. At six months follow-up, imaging showed near resolution of ground-glass opacities.

| S-EPMC7394920 | biostudies-literature

The inverse association of state cannabis vaping prevalence with the e-cigarette or vaping product-use associated lung injury.

Project description:The e-cigarette or vaping product-use-associated lung injury (EVALI) epidemic was primarily associated with the use of e-cigarettes containing tetrahydrocannabinol (THC)- the principal psychoactive substance in cannabis, and vitamin-E-acetate- an additive sometimes used in informally sourced THC-containing e-liquids. EVALI case burden varied across states, but it is unclear whether this was associated with state-level cannabis vaping prevalence. We, therefore, used linear regression models to assess the cross-sectional association between state-level cannabis vaping prevalence (obtained from the 2019 behavioral Risk Factor Surveillance System) and EVALI case burden (obtained from the Centers for Disease Control and Prevention) adjusted for state cannabis policies. Cannabis vaping prevalence ranged from 1.14%(95%CI, 0.61%-2.12%) in Wyoming to 3.11%(95%CI, 2.16%-4.44%) in New Hampshire. EVALI cases per million population ranged from 1.90(0.38-3.42) in Oklahoma to 59.10(19.70-96.53) in North Dakota. There was no significant positive association but an inverse association between state cannabis vaping prevalence and EVALI case burden (Coefficient, -18.6; 95%CI, -37.5-0.4; p-value, 0.05). Thus, state-level cannabis vaping prevalence was not positively associated with EVALI prevalence, suggesting that there may not be a simple direct link between state cannabis vaping prevalence and EVALI cases, but rather the relationship is likely more nuanced and possibly reflective of access to informal sources of THC-containing e-cigarettes.

| S-EPMC9576092 | biostudies-literature

E-Cigarette, or Vaping, Product Use-associated Lung Injury: A Response to Perez and Crotty Alexander.

Project description: Not available

| S-EPMC7328172 | biostudies-literature

E-Cigarette or Vaping Product Use-associated Lung Injury: Developing a Research Agenda. An NIH Workshop Report.

Project description:The NHLBI convened a working group on October 23, 2019, to identify the most relevant and urgent research priorities and prevailing challenges in e-cigarette or vaping product use-associated lung injury (EVALI). Experts across multiple disciplines discussed the complexities of the EVALI outbreak, identified research priorities, and recommended strategies to address most effectively its causal factors and improve diagnosis, treatment, and prevention of this disease. Many research priorities were identified, including the need to create national and international registries of patients with EVALI, to track accurately those affected and assess outcomes. The group concluded that biospecimens from subjects with EVALI are urgently needed to help define EVALI pathogenesis and that vaping has disease risks that are disparate from smoking, with the occurrence of EVALI highlighting the importance of broadening e-cigarette research beyond comparators to smoking-related diseases.

| S-EPMC7491408 | biostudies-literature

Reply: E-Cigarette, or Vaping, Product Use-associated Lung Injury: A Response to Perez and Crotty Alexander.

Project description: Not available

| S-EPMC7328184 | biostudies-literature

Patient Characteristics and Product Use Behaviors Among Persons with E-cigarette, or Vaping, Product Use-Associated Lung Injury - Indiana, June October 2019.

Project description:As of December 4, 2019, a total of 2,291 cases of hospitalized e-cigarette, or vaping, product use-associated lung injury (EVALI) have been reported from 50 states, the District of Columbia, and two U.S. territories (Puerto Rico and the U.S. Virgin Islands) (1). State health departments, including the Indiana State Department of Health (ISDH), are working with their local health departments and with CDC, the Food and Drug Administration, and other clinical and public health partners in investigating this outbreak of EVALI. On August 7, 2019, ISDH issued an advisory regarding patients hospitalized in Wisconsin with severe acute lung injury who reported the use of e-cigarette, or vaping, products (2); health care providers were requested to notify ISDH of similar cases. On August 8, 2019, ISDH received reports of five similar cases among Indiana residents. Suspected cases EVALI reported to ISDH were investigated further only among patients who required hospitalization. Established case definitions were used to classify cases.* Medical record abstractions and patient interviews were completed using nationally standardized forms to ascertain patient characteristics, medical care received, and product-use behaviors.

| S-EPMC6919291 | biostudies-literature

A Unique Case of Secondary Pulmonary Alveolar Proteinosis after E-Cigarette, or Vaping, Product Use-associated Lung Injury.

Project description: Not available

| S-EPMC7710329 | biostudies-literature

Lipid-laden Macrophages Are Not Unique to Patients with E-Cigarette or Vaping Product Use-associated Lung Injury.

Project description: Not available

| S-EPMC8048758 | biostudies-literature

Clinical Characterization of E-Cigarette, or Vaping, Product Use-associated Lung Injury in 36 Patients in Pittsburgh, Pennsylvania.

Project description: Not available

| S-EPMC7233355 | biostudies-literature